The FDA granted Pfizer and partner BioNTech full approval for their vaccine last week. Meanwhile, there were reports from Reuters that Novavax (NVAX) may face additional delays in their EU approval. This is signaling that manufacturing issues may once again be concerning for NVAX.
Reuters reported that source from Europe’s EMA said that Novavax has chang…